Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (383)	3/21/2013 8:35:07 AM
From: Arthur Radley	Respond to of 507

seekingalpha.com Detailed article about the various programs that NKTR is involved. Writer indicates he works in the health field--could be hospital orderly, for all I know--but the article is lengthy and detailed.

To: ghmm who wrote (383)	3/21/2013 8:01:55 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 507

Nice move in the stock today--got within a few pennies of breaking out above a new 52 week high. I'm assuming the move was helped by the Astra Zeneca forum today where they updated their game plan for future growth. I think it safe to assume there was some 'spin' in their extensive presentation..but it was nice to see what they project for the NKTR drug. They project total revenue topping $1 billion dollars...making a nice chunk of change for NKTR. If you want to wade through the AZN presentation listed on their home page........the reference to NKTR is found on pages 98 and 102. If we get the FDA nod for the MAPP/Allergan drug that is scheduled for April 15th---we should see a nice pop in the stock! One can hope! I bought my wife a new Avalon hybrid today---so I hope NKTR delivers!